Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on July 24, 2013, reporting events occurring on July 23, 2013. The filing details a material definitive agreement and a registered direct public offering of common stock and warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $5.7 million from the sale of 11,400,000 shares of common stock and warrants to purchase 3,990,000 shares.
- Net Proceeds: Expected to be approximately $5.2 million after deducting placement agent fees, expenses, and estimated offering costs.
- Offering Price: $0.50 per unit (one share of common stock plus a warrant to purchase 0.35 shares).
- Warrant Exercise Price: $0.59 per share.
- Placement Agent Fees: 6% of gross proceeds plus a warrant for 456,000 shares (4% of shares sold) and expense reimbursement up to $50,000 (1% of gross proceeds).
Material Changes
The filing reports the execution of a securities purchase agreement with institutional investors on July 23, 2013. This represents a significant capital raise event distinct from prior periods, aimed at securing funding through a registered direct offering. The company entered into an engagement letter with H.C. Wainwright & Co., LLC on July 18, 2013, to facilitate this transaction.
Outlook, Risks, and Unusual Items
- Closing Date: The offering is expected to close on or about July 26, 2013, subject to customary closing conditions.
- Warrant Terms: Warrants are exercisable beginning six months after issuance and expire five years from issuance. Terms are adjustable for stock splits or dividends.
- Regulatory Disclosure: The press release issued on July 24, 2013, is provided under Regulation FD but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
- Legal Opinion: Patton Boggs LLP provided a legal opinion regarding the legality of the issuance.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected July 26, 2013) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and ownership limitations.
- Confirm the final calculation of net proceeds after all fees and expenses are deducted.
- Monitor future filings for the impact of the new share issuance on existing shareholder dilution.